The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering.
1. Chapter 1: Introduction to biologics and monoclonal antibodies - p. Cover 2. Chapter 2: Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins - p. 14 3. Chapter 3: Antibody structure–function relationships - p. 36 4. Chapter 4: Fundamental technologies for antibody engineering - p. 56 5. Chapter 5: Sources of antibody variable chains - p. 76 6. Chapter 6: Variable chain engineering – humanization and optimization approaches - p. 109 7. Chapter 7: Antibody interactions with the immune system - p. 129 8. Chapter 8: Monoclonal antibody targets and mechanisms of action - p. 162 9. Chapter 9: Therapeutic antibody classes - p. 196 10. Chapter 10: Antibody Fc engineering for optimal antibody performance - p. 223 11. Chapter 11: IgG glycans and glyco-engineering - p. 249 12. Chapter 12: Antibody fragments as therapeutics - p. 264 13. Chapter 13: Multiple antibody and multi-specificity approaches - p. 297 14. Chapter 14: FcFPs and similar constructs using Fc - p. 328 15. Chapter 15: Antibody-drug conjugates - p. 343 16. Chapter 16: Development issues: antibody stability, developability, immunogenicity, and comparability - p. 375 17. Chapter 17: Interactions of human IgGs with non-human systems - p. 403 18. Chapter 18: Cell line development - p. 420 19. Chapter 19: Issues facing therapeutic monoclonal antibodiesfor the future - p. 437 20. Useful public websites related to antibody engineering - p. 453 21. References - p. 457 22. Index - p. 457
The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering.
1. Chapter 1: Introduction to biologics and monoclonal antibodies - p. Cover 2. Chapter 2: Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins - p. 14 3. Chapter 3: Antibody structure–function relationships - p. 36 4. Chapter 4: Fundamental technologies for antibody engineering - p. 56 5. Chapter 5: Sources of antibody variable chains - p. 76 6. Chapter 6: Variable chain engineering – humanization and optimization approaches - p. 109 7. Chapter 7: Antibody interactions with the immune system - p. 129 8. Chapter 8: Monoclonal antibody targets and mechanisms of action - p. 162 9. Chapter 9: Therapeutic antibody classes - p. 196 10. Chapter 10: Antibody Fc engineering for optimal antibody performance - p. 223 11. Chapter 11: IgG glycans and glyco-engineering - p. 249 12. Chapter 12: Antibody fragments as therapeutics - p. 264 13. Chapter 13: Multiple antibody and multi-specificity approaches - p. 297 14. Chapter 14: FcFPs and similar constructs using Fc - p. 328 15. Chapter 15: Antibody-drug conjugates - p. 343 16. Chapter 16: Development issues: antibody stability, developability, immunogenicity, and comparability - p. 375 17. Chapter 17: Interactions of human IgGs with non-human systems - p. 403 18. Chapter 18: Cell line development - p. 420 19. Chapter 19: Issues facing therapeutic monoclonal antibodiesfor the future - p. 437 20. Useful public websites related to antibody engineering - p. 453 21. References - p. 457 22. Index - p. 457
